Predicting Venous Thromboembolism in Primary Care

Stefano Barco; Stavros V. Konstantinides

doi:10.1055/s-0040-1708485

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2020; 120(04): 531-533
DOI: 10.1055/s-0040-1708485

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Predicting Venous Thromboembolism in Primary Care

Authors

Stefano Barco

¹Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany

²Clinic of Angiology, University Hospital of Zurich, Zurich, Switzerland
Stavros V. Konstantinides

¹Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany

³Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece

Abstract

Full Text

References

References
1 Ageno W, Haas S, Weitz JI. , et al; GARFIELD-VTE investigators. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE Registry. Thromb Haemost 2019; 119 (02) 319-327
2 Bikdeli B, Jimenez D, Hawkins M. , et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
3 Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE. European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 2016; 115 (04) 800-808
4 Roetker NS, Lutsey PL, Zakai NA, Alonso A, Adam TJ, MacLehose RF. All-cause mortality risk with direct oral anticoagulants and warfarin in the primary treatment of venous thromboembolism. Thromb Haemost 2018; 118 (09) 1637-1645
5 Blondon M, Spirk D, Kucher N. , et al. Comparative performance of clinical risk assessment models for hospital-acquired venous thromboembolism in medical patients. Thromb Haemost 2018; 118 (01) 82-89
6 Li A, Kuderer NM, Garcia DA. , et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. J Thromb Haemost 2019; 17 (12) 2141-2151
7 Barbarawi M, Zayed Y, Kheiri B. , et al. The role of anticoagulation in venous thromboembolism primary prophylaxis in patients with malignancy: a systematic review and meta-analysis of randomized controlled trials. Thromb Res 2019; 181: 36-45
8 Dentali F, Fontanella A, Cohen AT. , et al. Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thromb Haemost 2020; 120 (04) 692-701
9 Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J 2014; 35 (29) 1925-1931
10 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26 (06) 565-574
11 Spyropoulos AC, Barnathan ES, Raskob GE. ; MARINER Investigators. Thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (23) 2280
12 Cohen AT, Spiro TE, Büller HR. , et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
13 Cohen AT, Harrington RA, Goldhaber SZ. , et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
14 Goldhaber SZ, Leizorovicz A, Kakkar AK. , et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011; 365 (23) 2167-2177
15 Hull RD, Schellong SM, Tapson VF. , et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010; 153 (01) 8-18
16 Schindewolf M, Weitz JI. Broadening the categories of patients eligible for extended venous thromboembolism treatment. Thromb Haemost 2020; 120 (01) 14-26
17 Konstantinides SV, Meyer G, Becattini C. , et al; ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
18 Mai V, Guay CA, Perreault L. , et al. Extended anticoagulation for VTE: a systematic review and meta-analysis. Chest 2019; 155 (06) 1199-1216
19 Squizzato A, Agnelli G, Campanini M. , et al; FADOI-NoTEVole Study Group. Prophylaxis of venous thromboembolism after hospital discharge in internal medicine: findings from the observational FADOI-NoTEVole study. Thromb Haemost 2019; 119 (12) 2043-2052
20 Barco S, Mahmoudpour SH, Valerio L. , et al. Trends in mortality related to pulmonary embolism in the European Region, 2000-15: analysis of vital registration data from the WHO Mortality Database. Lancet Respir Med 2019; S2213-2600(19)30354-6
21 Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. ; ISTH Steering Committee for World Thrombosis Day. Global public awareness of venous thromboembolism. J Thromb Haemost 2015; 13 (08) 1365-1371